Kinetic studies of 25-hydroxy-19-nor-vitamin D3 and 1α,25-dihydroxy-19-nor-vitamin D3 hydroxylation by CYP27B1 and CYP24A1

Drug Metabolism and Disposition

Volumn 35, Issue 9, 2007, Pages 1482-1488

  Urushino, Naoko ^a   Nakabayashi, Sachie ^b   Arai, Midori A ^c   Kittaka, Atsushi ^c   Chen, Tai C ^d   Yamamoto, Keiko ^e,h   Hayashi, Keiko ^b   Kato, Shigeaki ^f   Ohta, Miho ^g   Kamakura, Masaki ^a   Ikushiro, Shinichi ^a   Sakaki, Toshiyuki ^a,b  

^a KYOTO UNIVERSITY   (Japan)

^b TOYAMA PREFECTURAL UNIVERSITY   (Japan)

^c TEIKYO UNIVERSITY   (Japan)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^f UNIVERSITY OF TOKYO   (Japan)

^g Soai University   (Japan)

^h SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1ALPHA,25 DIHYDROXY 19 NORVITAMIN D 3; 25 HYDROXY 19 NORVITAMIN D 3; CALCIFEDIOL; COLECALCIFEROL DERIVATIVE; CYTOCHROME P450; CYTOCHROME P450 24A1; CYTOCHROME P450 27B1; DRUG METABOLITE; UNCLASSIFIED DRUG;

ARTICLE; CELL FREE SYSTEM; CELL MIGRATION; CELL STRAIN; CONTROLLED STUDY; DRUG DEGRADATION; DRUG DETERMINATION; DRUG HYDROXYLATION; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO SELECTION; KINETICS; MALE; PRIORITY JOURNAL; PROSTATE;

25-HYDROXYVITAMIN D3 1-ALPHA-HYDROXYLASE; ANIMALS; CALCITRIOL; CARBON MONOXIDE; CATTLE; CELL LINE; CELL PROLIFERATION; CHOLECALCIFEROL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; ESCHERICHIA COLI; HUMANS; HYDROXYLATION; KINETICS; MALE; MODELS, MOLECULAR; PLASMIDS; PROSTATE; THYMUS GLAND;

HUMAN PAPILLOMAVIRUS;

EID: 34548077902     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.015602     Document Type: Article

References (41)

1. Abe-Hashimoto J, Kikuchi T, Matsumoto T, Nishii Y, Ogata E, and Ikeda K (1993) Antitumor effect of 22-oxa-calcitriol, a noncalcemic analogue of calcitriol, in athymic mice implanted with human breast carcinoma and its synergism with tamoxifen. Cancer Res 53:2534-2537.
2. Akiyoshi-Shibata M, Sakaki T, Ohyama Y, Noshiro M, Okuda K, and Yabusaki Y (1994) Further oxidation of hydroxycalcidiol by calcidiol 24-hydroxylase. Eur J Biochem 224:335-343.
3. 3: efficient synthesis with Julia olefination, evaluation of biological activity and development of new analyzing system for co-activator recruitment. Anticancer Res 26:2621-2632.
4. 3 analogs and their antiproliferative activities on prostate cells. Heterocycles 66:469-479.
5. 3, inhibits the proliferation of primary prostatic epithelial cells. Cancer Epidemiol Biomarkers Prev 9:265-270.
6. 3 analogues: a novel class of potent regulators of cell growth and immune responses. Biochem Pharmacol 49:621-624.
7. 3 and its analogs. J Bone Miner Res 9:1277-1288.
8. Bouillon R, Okamura WH, and Norman AW (1995) Structure-function relationships in the vitamin D endocrine system. Endocr Rev 16:200-257.
9. 2 as therapeutic agents for prostate cancer. Clin Cancer Res 6:901-908.
10. 3, in Vitamin D (Feldman D, Pike JW, and Glorieux FH eds), 2nd ed, pp 1543-1555. Elsevier, Burlington, MA.
11. 3: A-ring structural motif that modulates interactions of vitamin D receptor with transcriptional coactivators. Org Biomol Chem 1:1863-1869.
12. Goodsell DS, Morris GM, and Olson AJ (1996) Automated docking of flexible ligands: applications of AutoDock. J Mol Recognit 9:1-5.
13. Hamamoto H, Kusudo T, Urushino N, Masuno H, Yamamoto K, Yamada S, Kamakura M, Ohta M, Inouye K, and Sakaki T (2006) Structure-function analysis of vitamin D 24-hydroxylase (CYP24A1) by site-directed mutagenesis: amino acid resides responsible for species-based difference of CYP24A1 between humans and rats. Mol Pharmacol 70:120-128.
14. Harmata M and Barnes CL (1990) Molecular clefts. 2. An analogue of Kagan's ether as a molecular cleft: synthesis and clathrate formation with ethyl acetate. Tetrahedron Lett 31:1825-1828.
15. 3 metabolite with high affinity for the 1,25-dihydroxyvitamin D specific cytosol receptor. Biochemistry 22:245-250.
16. Hsu JY, Feldman D, McNeal JE, and Peehl DM (2001) Reduced 1α-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Cancer Res 61:2852-2856.
17. 3: remarkably high affinity to vitamin D receptor. Org Lett 2:2619-2622.
18. 3 and their 20-epimers: unique activity profiles depending on the stereochemistry of the A-ring and at C-20. J Med Chem 43:4247-4265.
19. 3 by CYP24A1. Biochem Biophys Res Commun 321:774-782.
20. 2. Am J Kidney Dis 32(Suppl 2):S48-S54.
21. 3 in seven human prostatic carcinoma cell lines. Clin Cancer Res 1:997-1003.
22. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. J Biol Chem 118:397-404.
23. Ono K, Yoshida A, Saito N, Fujishima T, Honzawa S, Suhara Y, Kishimoto S, Sugiura T, Waku K, Takayama H, et al. (2003) Efficient synthesis of 2-modified 1α,25-dihydroxy-19-norvitamin D3 with Julia olefination: high potency in induction of differentiation on HL-60 cells. J Org Chem 68:7407-7415.
24. Plum LA, Prahl JM, Ma X, Sicinski RR, Gowlugari S, Clagett-Dame M, and DeLuca HF (2004) Biologically active noncalcemic analogs of 1α,25- dihydroxyvitamin D with an abbreviated side chain containing no hydroxyl. Proc Natl Acad Sci U S A 101:6900-6904.
25. 3 catalyzed by human CYP24. Eur J Biochem 267:6158-6165.
26. 3 to calcitroic acid. Eur J Biochem 262:43-48.
27. 3 1α-hydroxylase expressed in Escherichia coli. Eur J Biochem 259:731-738.
28. 25 bond cleavage catalyzed by human CYP24A1. Biochemistry 43:4530-4537.
29. 3 1α-hydroxylase: co-expression with adrenodoxin and NADPH-adrenodoxin reductase in Escherichia coli. Eur J Biochem 265:950-956.
30. 3 by human CYP27A1. Biochem Biophys Res Commun 273:977-984.
31. 2 (paricalcitol) in advanced, androgen-insensitive prostate cancer. Clin Cancer Res 11:8680-8685.
32. 3. Endocrinology 136:20-26.
33. 3 analogues and their docking to vitamin D receptors. J Org Chem 66:8760-8771.
34. Uchida E, Kagawa N, Sakaki T, Urushino N, Sawada N, Kamakura M, Ohta M, Kato S, and Inouye K (2004) Purification and characterization of mouse CYP27B1 overproduced by an Escherichia coli system coexpressing molecular chaperonins GroEL/ES. Biochem Biophys Res Commun 323:505-511.
35. Urushino N, Yamamoto K, Kagawa N, Ikushiro S, Kamakura M, Yamada S, Kato S, Inouye K, and Sakaki T (2006) Interaction between mitochondrial CYP27B1 and adrenodoxin: role of arginine 458 of mouse CYP27B1. Biochemistry 45:4405-4412.
36. Wang L, Whitlatch LW, Flanagan JN, Holick MF, and Chen TC (2003) Vitamin D autocrine system and prostate cancer. Recent Results Cancer Res 164:223-237.
37. Whitlatch LW, Young MV, Schwartz GG, Flanagan JN, Burnstein KL, Lokeshwar BL, Rich ES, Holick MF, and Chen TC (2002) 25-Hydroxyvitamin D-1α-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer. J Steroid Biochem Mol Biol 8:135-140.
38. Yamada S, Shimizu M, and Yamamoto K (2003) Structure-function relationships of vitamin D including ligand recognition by the vitamin D receptor. Med Res Rev 23:89-115.
39. 3 whose mutation causes vitamin D-dependent rickets type 1. J Biol Chem, 280:30511-30516.
40. Young MV, Schwartz GG, Wang L, Jamieson DP, Whitlatch LW, Flanagan JN, Lokeshwar BL, Holick MF, and Chen TC (2004) The prostate 25-hydroxyvitamin D-1α-hydroxylase is not influenced by parathyroid hormone and calcium: implications for prostate cancer chemoprevention by vitamin D. Carcinogenesis 25:967-971.
41. 3 revealed by microarray analysis. J Biol Chem 280:35458-354685.